Title: Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Authors: Choueiri, Toni K ×
Escudier, Bernard
Powles, Thomas
Mainwaring, Paul N
Rini, Brian I
Donskov, Frede
Hammers, Hans
Hutson, Thomas E
Lee, Jae-Lyun
Peltola, Katriina
Roth, Bruce J
Bjarnason, Georg A
Géczi, Lajos
Keam, Bhumsuk
Maroto, Pablo
Heng, Daniel Y C
Schmidinger, Manuela
Kantoff, Philip W
Borgman-Hagey, Anne
Hessel, Colin
Scheffold, Christian
Schwab, Gisela M
Tannir, Nizar M
Motzer, Robert J
Schöffski, Patrick #
Issue Date: 5-Nov-2015
Series Title: New England Journal of Medicine vol:373 issue:19 pages:1814-23
Article number: 10.1056/NEJMoa1510016
Abstract: Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs. This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.pdf Published 532KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science